Build Your Comparison

Side-by-side financial analysis
FLGC logo
FLGC
DBVT logo
DBVT
ALKS logo
ALKS
TLRY logo
TLRY
Try popular comparisons:

Stock Comparison

FLGC vs DBVT vs ALKS vs TLRY

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
FLGC
Flora Growth Corp.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$88M
5Y Perf.-99.8%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$919M
5Y Perf.-64.1%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$7.50B
5Y Perf.+32.8%
TLRY
Tilray Brands, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$551M
5Y Perf.-52.8%

FLGC vs DBVT vs ALKS vs TLRY — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
FLGC logoFLGC
DBVT logoDBVT
ALKS logoALKS
TLRY logoTLRY
IndustryDrug Manufacturers - Specialty & GenericBiotechnologyBiotechnologyDrug Manufacturers - Specialty & Generic
Market Cap$88M$919M$7.50B$551M
Revenue (TTM)$14M$0.00$1.56B$1.17B
Net Income (TTM)$-120M$-168M$153M$-2.95B
Gross Margin43.3%65.4%28.0%
Operating Margin-30.7%12.3%-266.0%
Forward P/E31.5x
Total Debt$54M$22M$70M$451M
Cash & Equiv.$6M$194M$1.12B$304M

FLGC vs DBVT vs ALKS vs TLRYLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

FLGC
DBVT
ALKS
TLRY
StockMay 21Mar 26Return
Flora Growth Corp. (FLGC)1000.2-99.8%
DBV Technologies S.… (DBVT)10035.9-64.1%
Alkermes plc (ALKS)100132.8+32.8%
Tilray Brands, Inc. (TLRY)10047.2-52.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: FLGC vs DBVT vs ALKS vs TLRY

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ALKS leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Tilray Brands, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇ALKS emerged as the overall leader. Track its performance:
FLGC
Flora Growth Corp.
The Specific-Use Pick

FLGC plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
DBVT
DBV Technologies S.A.
The Income Pick

DBVT is the clearest fit if your priority is income & stability.

  • Dividend streak 0 yrs, beta 1.12
Best for: income & stability
ALKS
Alkermes plc
The Long-Run Compounder

ALKS carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.

  • 7.4% 10Y total return vs TLRY's -78.9%
  • Lower volatility, beta 0.88, Low D/E 3.8%, current ratio 3.55x
  • Beta 0.88, current ratio 3.55x
  • 9.8% margin vs FLGC's -8.3%
Best for: long-term compounding and sleep-well-at-night
TLRY
Tilray Brands, Inc.
The Growth Play

TLRY is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 4.8%, EPS growth -6.5%, 3Y rev CAGR 12.5%
  • 4.8% revenue growth vs DBVT's -100.0%
  • +11.3% vs FLGC's -74.3%
Best for: growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthTLRY logoTLRY4.8% revenue growth vs DBVT's -100.0%
Quality / MarginsALKS logoALKS9.8% margin vs FLGC's -8.3%
Stability / SafetyALKS logoALKSBeta 0.88 vs FLGC's 3.12, lower leverage
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)TLRY logoTLRY+11.3% vs FLGC's -74.3%
Efficiency (ROA)ALKS logoALKS5.4% ROA vs FLGC's -192.1%, ROIC 18.9% vs -5.5%

FLGC vs DBVT vs ALKS vs TLRY — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

FLGCFlora Growth Corp.
FY 2021
Pharmaceuticals and Nutraceuticals
100.0%$2M
DBVTDBV Technologies S.A.

Segment breakdown not available.

ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
TLRYTilray Brands, Inc.
FY 2025
Cannabis Segment
36.1%$331M
Distribution Revenue
29.6%$271M
Beverage Alcohol Business
27.7%$253M
Wellness Business
6.6%$60M

FLGC vs DBVT vs ALKS vs TLRY — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGDBVT

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 5 of 6 comparable metrics.

ALKS and DBVT operate at a comparable scale, with $1.6B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to FLGC's -8.3%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricFLGC logoFLGCFlora Growth Corp.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcTLRY logoTLRYTilray Brands, In…
RevenueTrailing 12 months$14M$0$1.6B$1.2B
EBITDAEarnings before interest/tax-$4M-$112M$212M-$3.0B
Net IncomeAfter-tax profit-$120M-$168M$153M-$2.9B
Free Cash FlowCash after capex-$9M-$151M$392M-$94M
Gross MarginGross profit ÷ Revenue+43.3%+65.4%+28.0%
Operating MarginEBIT ÷ Revenue-30.7%+12.3%-2.7%
Net MarginNet income ÷ Revenue-8.3%+9.8%-2.5%
FCF MarginFCF ÷ Revenue-63.5%+25.1%-8.1%
Rev. Growth (YoY)Latest quarter vs prior year-2.6%+28.2%+3.0%
EPS Growth (YoY)Latest quarter vs prior year+2.6%+91.5%-4.1%+70.7%
ALKS leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

TLRY leads this category, winning 2 of 3 comparable metrics.
MetricFLGC logoFLGCFlora Growth Corp.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcTLRY logoTLRYTilray Brands, In…
Market CapShares × price$88M$919M$7.5B$551M
Enterprise ValueMkt cap + debt − cash$87M$747M$6.4B$698M
Trailing P/EPrice ÷ TTM EPS-5.55x-0.59x31.46x-0.14x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple22.94x
Price / SalesMarket cap ÷ Revenue1.49x5.08x0.49x
Price / BookPrice ÷ Book value/share19.61x0.51x4.17x0.21x
Price / FCFMarket cap ÷ FCF15.61x
TLRY leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 8 of 9 comparable metrics.

ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-3 for FLGC. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to FLGC's 0.76x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs FLGC's 3/9, reflecting strong financial health.

MetricFLGC logoFLGCFlora Growth Corp.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcTLRY logoTLRYTilray Brands, In…
ROE (TTM)Return on equity-3.3%-130.2%+8.8%-136.5%
ROA (TTM)Return on assets-192.1%-89.0%+5.4%-100.6%
ROICReturn on invested capital-5.5%+18.9%-66.2%
ROCEReturn on capital employed-6.9%-145.7%+14.2%-78.1%
Piotroski ScoreFundamental quality 0–93474
Debt / EquityFinancial leverage0.76x0.13x0.04x0.22x
Net DebtTotal debt minus cash$48M-$172M-$1.0B$147M
Cash & Equiv.Liquid assets$6M$194M$1.1B$304M
Total DebtShort + long-term debt$54M$22M$70M$451M
Interest CoverageEBIT ÷ Interest expense-18.87x-189.82x32.30x-89.43x
ALKS leads this category, winning 8 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — ALKS and TLRY each lead in 3 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $18,423 today (with dividends reinvested), compared to $25 for FLGC. Over the past 12 months, TLRY leads with a +1134.0% total return vs FLGC's -74.3%. The 3-year compound annual growth rate (CAGR) favors TLRY at 45.0% vs FLGC's -62.9% — a key indicator of consistent wealth creation.

MetricFLGC logoFLGCFlora Growth Corp.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcTLRY logoTLRYTilray Brands, In…
YTD ReturnYear-to-date+5.3%-18.5%+59.2%-51.3%
1-Year ReturnPast 12 months-74.3%+57.7%+53.4%+1134.0%
3-Year ReturnCumulative with dividends-94.9%-24.6%+38.7%+205.2%
5-Year ReturnCumulative with dividends-99.8%-74.4%+84.2%-72.0%
10-Year ReturnCumulative with dividends-99.8%-89.9%+7.4%-78.9%
CAGR (3Y)Annualised 3-year return-62.9%-9.0%+11.5%+45.0%
Evenly matched — ALKS and TLRY each lead in 3 of 6 comparable metrics.

Risk & Volatility

ALKS leads this category, winning 2 of 2 comparable metrics.

ALKS is the less volatile stock with a 0.88 beta — it tends to amplify market swings less than FLGC's 3.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 98.3% from its 52-week high vs FLGC's 15.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricFLGC logoFLGCFlora Growth Corp.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcTLRY logoTLRYTilray Brands, In…
Beta (5Y)Sensitivity to S&P 5003.12x1.12x0.88x1.93x
52-Week HighHighest price in past year$47.00$26.18$45.76$15.70
52-Week LowLowest price in past year$5.86$8.50$25.17$0.35
% of 52W HighCurrent price vs 52-week peak+15.3%+59.3%+98.3%+30.1%
RSI (14)Momentum oscillator 0–10047.137.569.533.8
Avg Volume (50D)Average daily shares traded11K225K1.9M4.9M
ALKS leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: DBVT as "Buy", ALKS as "Buy", TLRY as "Hold". Consensus price targets imply 198.3% upside for DBVT (target: $46) vs 10.0% for ALKS (target: $50).

MetricFLGC logoFLGCFlora Growth Corp.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcTLRY logoTLRYTilray Brands, In…
Analyst RatingConsensus buy/hold/sellBuyBuyHold
Price TargetConsensus 12-month target$46.33$49.50$10.00
# AnalystsCovering analysts152820
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises00
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.4%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ALKS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TLRY leads in 1 (Valuation Metrics). 1 tied.

Best OverallAlkermes plc (ALKS)Leads 3 of 6 categories
Loading custom metrics...

FLGC vs DBVT vs ALKS vs TLRY: Key Questions Answered

8 questions · data-driven answers · updated daily

01

Is FLGC or DBVT or ALKS or TLRY a better buy right now?

For growth investors, Tilray Brands, Inc.

(TLRY) is the stronger pick with 4. 8% revenue growth year-over-year, versus -75. 6% for Flora Growth Corp. (FLGC). Alkermes plc (ALKS) offers the better valuation at 31. 5x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — FLGC or DBVT or ALKS or TLRY?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +84.

2%, compared to -99. 8% for Flora Growth Corp. (FLGC). Over 10 years, the gap is even starker: ALKS returned +7. 4% versus FLGC's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — FLGC or DBVT or ALKS or TLRY?

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 0.

88β versus Flora Growth Corp. 's 3. 12β — meaning FLGC is approximately 255% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 76% for Flora Growth Corp. — giving it more financial flexibility in a downturn.

04

Which is growing faster — FLGC or DBVT or ALKS or TLRY?

By revenue growth (latest reported year), Tilray Brands, Inc.

(TLRY) is pulling ahead at 4. 8% versus -75. 6% for Flora Growth Corp. (FLGC). On earnings-per-share growth, the picture is similar: Flora Growth Corp. grew EPS 100. 0% year-over-year, compared to -651. 7% for Tilray Brands, Inc.. Over a 3-year CAGR, TLRY leads at 12. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — FLGC or DBVT or ALKS or TLRY?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -266. 3% for Tilray Brands, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -277. 9% for TLRY. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — FLGC or DBVT or ALKS or TLRY?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is FLGC or DBVT or ALKS or TLRY better for a retirement portfolio?

For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

88)). Flora Growth Corp. (FLGC) carries a higher beta of 3. 12 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKS: +7. 4%, FLGC: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between FLGC and DBVT and ALKS and TLRY?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.